HEALTH
- Share via
Astra Signs Pact for Ulcer Research: The Swedish pharmaceutical maker said it signed an agreement with Genome Therapeutics Corp. to research new treatment methods for a bacterium believed to be a cause of peptic ulcers. Research will concentrate on the H. pylori bacterium, Astra said. Waltham, Mass.-based Genome specializes in identifying and characterizing genes, with a major program focused on the H. pylori gene, Astra said. Under the pact, Astra will pay up to $20 million related to joint research work and for marketing rights to products created under the pact that are based on Genome’s technology. Genome will receive royalties on sales of such products, Astra said. Genome shares closed up 25 cents at $8 on the Nasdaq.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.